Blue Cross Blue Shields of Wyoming
Blue Cross Blue Shields of Wyoming

Site Section: Providers

Provider Update – Redirection of Care & Holiday Closures

Redirection of Care

Blue Cross Blue Shield of Wyoming is introducing a new redirection of care program for certain medications. When clinically appropriate services will be authorized in the most cost-effective setting, such as an Infusion Center, providers office, or via Home Health. If needed, BCBSWY will assist members with finding an appropriate site for care.

Please note, redirection of care does not affect your patient’s prescription drug benefits.

If a member is affected by this program, it will be noted in the authorization letter. 

Who is Impacted:
As of January 1, 2022, the list below are the medications that will be subject to the redirection of care program for administration in the most cost-effective setting:

Neulasta Remicade
Avastin Rituxab
Herceptin Keytruda
Ocrevus Opdivo
Somatuline Soliris

This program will go into effect with new prescriptions or upon authorization renewal. Typically, medical authorizations expire one year from the date of the authorization.          

Questions:

We have a Redirection of Care Team. If you’re currently taking one of these medications and have questions or concerns, please call 307-823-6095.

Upcoming Holiday Closures

BCBSWY will be closed on Friday, December 24 and Friday, December 31 in observance of the Christmas and New Year holiday.

Site of Care Infusion Drugs

Blue Cross Blue Shield of Wyoming’s site of care program requires certain services that may have been received in a hospital setting to now only be authorized in the most cost-effective setting, such as an infusion center, provider’s office, or via home health including the use of subcutaneous injectables. If needed, BCBSWY will assist members with finding an appropriate site for care. All medications under this program require Prior Authorization.

If administration of the list of drugs below are not approved to be performed in an inpatient or outpatient hospital setting members can receive infusion treatments at facilities such as free-standing infusion center, doctor’s office, pharmacy, or via home health. Failure to receive the service in an approved location could result in the denial of claims. The financial responsibility of the denied amount will be the members responsibility.

Please be advised that while the medication may have been approved as medically appropriate, the member’s benefits may require this service be provided in specific locations.

If needed, our Site of Care Team can assist members with finding an appropriate site for care. Our team is available Monday-Friday, 8:00 am-5:00 pm, by calling 307-823-6095 to assist you.

Preferred Product Program

Beginning on 1/1/2026, some members may be required to receive preferred medications, including biosimilar medications for coverage. Biosimilar medications are medications that have active properties similar to the brand name medications but are typically less costly. Exceptions may apply during the prior authorization process when a contraindication is clinically documented by a health care provider.

All preferred products are listed within the medical policies posted on our public website. Below is a listing of the drug classes with preferred products.

Drug ClassPreferred Product
BevacizumabMvasi & Zirabev
RituximabRuxience, Truxima, Riabni
InfliximabAvsola, Inflectra
ViscosupplementsDurolane, Gelsyn-3, Supartz, Gel-One, Visco-3
DenosumabJubbonti, Stobclo
Immune Globulins IVOctagam, Gemmaked, Gamunix-C, Gammargard, Privigen
Immune Globulins SCHyqvia, Hizentra, Xembify, Cutaquig
UstekinumabSelarsdi, Yesintek, SteQueyma
Infused IronFeraheme, Ferrlecit, INFed, Venofer

 

This program will go into effect with new prescriptions or upon authorization renewal. Typically, medical authorizations expire one year from the date of the authorization.

Questions:
Your redirection of care team is available to members and providers. If you’re currently taking one of these medications or prescribing these medications and have questions or concerns, please call 307-823-6095.

Availity Provider Portal
Submit Prior Authorization requests online.
Go to Availity
Site of Care Form
Submit an exemption form.
Submit
Provider Resources

Ready to join our network?

Request an Application

Prior Authorization Requests

Propose inpatient stay and request specified services easily through Availity

Download the Online Training Guide
Or
Watch Prior Auth Videos

Participants of some health plans may have terms of coverage or benefits that differ from the information presented here.

The following information describes the general policies of Blue Cross Blue Shield of Wyoming and is provided for reference only. This information is NOT to be relied upon as prior authorization for health care services and is NOT A GUARANTEE OF PAYMENT. To verify coverage or benefits or determine prior authorization requirements for a participant, call 1-800-442-2376 or send an electronic inquiry through your established connection with your local Blue plan.

Admission Request

Notify BCBSWY of a proposed inpatient stay.

Learn More

Appeals and Peer-to-Peer Conversations

Request appeals for denied authorization requests or services.

Learn More

Continuity of Care for Enrollees – Authorization Transfer Request

This form is used to request transfer of authorization from a previous insurance carrier to BCBSWY.

Learn More

Dental Authorizations

Learn More

Prior Authorization Request Form

Learn More

Redirection of Care Infusion Drugs

Includes Redirection of Care Exemption Form.

Learn More

Rx Authorization Request​

Learn More

Service Request

Request approval from BCBSWY for specified services.

Learn More

Availity Provider Portal

Verify elgibility and benefits, submit claims, and more.

Go to Availity

WyoBlue Advantage 

Access the WyoBlue Advantage provider portal, find WyoBlue information, news, and more.

Visit WyoBlue Advantage
Provider Resources

Ready to join our network?

Request an Application

Provider Update – Codes, ID Cards and Closures

Provider Directory

Beginning Jan. 1, 2022, provider directory information must be reviewed and validated every 90 days, in accordance with the No Surprises Act. The information we’ll be looking for includes name, address, specialty, telephone number, and digital contact information of each health care provider or health care facility. Very soon, BCBSWY will share information on a new tool available in Availity to validate this information.

COVID-19 Vaccine Codes Updated

BCBSWY recently updated our COVID-19 vaccine codes to include pediatric vaccine codes. To review this information, click here.

Reminder! BCBSWY Member ID Cards

BCBSWY Member ID cards now include the amount of the in-network and out-of-network deductibles and out-of-pocket maximums. Subscriber numbers have not changed, however, please note that BCBSWY Members may offer their new Member ID card at their next medical appointment.

Upcoming Holiday Closures

BCBSWY will be closed on Thursday, November 25 and Friday, November 26 in observance of the Thanksgiving holiday.

 

BCBSWY Mailing Address:

PO Box 2266, Cheyenne, WY  82003-2266

Blue Cross Blue Shield of Wyoming is an independent licensee of the Blue Cross and Blue Shield Association

Practice Office Information

Contact Provider Services
Fewer Hassles. Better Service.
A new way to take care of your patients online--quickly and efficiently.
Go to Availity
2020 Update
BCBSWY Provider Manual
Download Manual

Telemedicine Services

Contact Provider Services
Fewer Hassles. Better Service.
A new way to take care of your patients online--quickly and efficiently.
Go to Availity
2020 Update
BCBSWY Provider Manual
Download Manual

New! COVID-19 Test Billing Guidance

The Families First Coronavirus Response Act (the FFCRA) and the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) require health plans to cover diagnostic testing of COVID-19. Coverage must be provided without any cost-share, prior authorization, or medical management requirements. The table below is provided to help understand which billing codes are appropriate for these services. Please note that antibody testing is appropriate as a diagnostic test in limited circumstances and will not be a benefitable service when conducted for return to work or surveillance purposes.

Asymptomatic and pre-surgical COVID-19 diagnostic testing is covered when medically appropriate and supported by the accepted standards of current medical practice.

See updates from 1/27/2021 below in red.

Test Type HCPCS/CPT Code Providers Eligible to Bill Is cost share waived? Is it a benefit?

COVID-19 Diagnostic Test
CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel U0001 CDC, State Lab YES YES
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC U0002 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making
use of high throughput technologies		 U0003 Laboratories only YES YES
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple
types or subtypes (includes all targets), non-CDC, making use of high throughput technologies		 U0004 Laboratories only YES YES
Infectious Agent Detection By Nucleic Acid (DNA Or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]), Amplified Probe Technique, CDC Or Non-CDC, Making Use Of High Throughput Technologies, Completed Within 2 Calendar Days From Date Of Specimen Collection (List Separately In Addition To Either HCPCS Code U0003 Or U0004) U0005 Laboratories only YES YES
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique 87635 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) (Coronavirus disease [COVID-19])

and influenza virus types A and B, multiplex

amplified probe technique

 87636 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) (Coronavirus disease [COVID-19]),

influenza virus types A and B, and respiratory

syncytial virus, multiplex amplified probe technique

 87637 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious agent antigen detection by immunoassay

technique, qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg,

SARS-CoV, SARS-CoV-2 [COVID-19])

 87426 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) 87811 Physician Offices, Urgent Care, Labs, Hospitals YES YES

Rapid COVID-19 Diagnostic Test
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC U0002-QW Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique 87635-QW Physician Offices, Urgent Care, Labs, Hospitals YES YES

Proprietary Lab Codes
Infectious disease (bacterial or viral respiratory

tract infection), pathogen-specific nucleic acid

(DNA or RNA), 22 targets including severe

acute respiratory syndrome coronavirus 2

(SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported

as detected or not detected

 

BioFire® Respiratory Panel 2.1 (RP2.1), BioFire® Diagnostics, BioFire® Diagnostics, LLC

 

BioFire® Respiratory Panel 2.1- EZ (RP2.1-EZ), BioFire® Diagnostics, BioFire® Diagnostics, LLC

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

0202U

 

 

 

0202U-QW

 

 

 

 Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

 

QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH

 0223U Physician Offices, Urgent Care, Labs, Hospitals YES YES
Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed

 

COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory

 0224U Physician Offices, Urgent Care, Labs, Hospitals Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment
Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected

 

ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc

 0225U Physician Offices, Urgent Care, Labs, Hospitals YES YES
Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum

 

Tru-Immune™, Ethos Laboratories, GenScript® USA Inc

 0226U Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected

 

Xpert® Xpress SARSCoV-2/Flu/RSV (SARS-CoV-2 & Flu targets only), Cepheid

 0240U Physician Offices, Urgent Care, Labs, Hospitals YES YES
Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected

 

Xpert® Xpress SARSCoV-2/Flu/RSV (all targets), Cepheid

 0241U Physician Offices, Urgent Care, Labs, Hospitals YES YES

Specimen Collection
Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source G2023 Laboratories only YES YES
– Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source G2024 Skilled Nursing
Lab on behalf of a Home Health Agency		 YES YES
Hospital Outpatient clinic visit specimen collection for severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) (Coronavirus disease[COVID-19]), any specimen source C9803 Hospital Outpatient YES YES
Handling and/or conveyance of specimen for transfer from the physician’s office to a laboratory 99000 Physician Offices YES YES
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory 99001 Mobile Unit
Walk-in Retail Health Clinic
Urgent Care
Emergency Room Hospital
Drive through testing		 YES YES

Antibody Tests
Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) 86328 Physician Offices, Urgent Care, Labs, Hospitals Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment
Neutralizing antibody, severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID19]); screen

 86408 Physician Offices, Urgent Care, Labs, Hospitals Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment
Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID19]); screen titer

 

 86409 Physician Offices, Urgent Care, Labs, Hospitals Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment
Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) 86769 Physician Offices, Urgent Care, Labs, Hospitals Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment Not covered unless the test is medically appropriate for diagnostic purposes based on an individual assessment

COVID-19 Billing Guidance – UPDATE!

COVID-19 Billing Guidance – UPDATE!

In order to ensure the proper cost share waiver of your COVID-19 testing claims, BCBSWY asks that providers include specimen handling codes on the claim if you are not performing these tests in-house. Providers can submit a corrected claim if these services were performed but omitted from previous claims.

Acceptable specimen handling codes are: G2023, G2024, C9803, 99000, and 99001. See COVID-19 Billing Guide for more details.

Please do not bill nurse level visits (99201 and 99211) in lieu of specimen collection codes, as these codes may not be properly identified as requiring cost share waivers.

For claims with treatment of COVID-19 defined as U07.1, BCBSWY will waive inpatient prior authorization requirements. Cost share waivers are dependent on a member’s benefit plan – see below for more information.

BCBSWY COVID-19 Response

Telemedicine

Because the health and safety of our community is of upmost of importance, BCBSWY continues to encourage telemedicine visits.

  • BCBSWY has extended our telemedicine benefits, including waiving member cost share,
    effective until August 31, 2020. Expanded telemedicine benefits include all BCBSWY fully
    insured members but is optional for self-funded plans.
  • For additional information on how BCBSWY is processing telemedicine benefits view this matrix.

COVID-19 Treatment

  • BCBSWY has extended our commitment to waive all member cost sharing and copayments for treatment, and inpatient hospital admissions, due to the diagnosis of COVID-19 for all fully insured members but is optional for self-funded plans, effective 4/1/20-8/31/20.

COVID-19 Testing & Billing

The Families First Coronavirus Response Act (the FFCRA) and the Coronavirus Aid, Relief, and
Economic Security Act (the CARES Act) require health plans to cover diagnostic testing of COVID-19.

  • Coverage must be provided without any cost-share, prior authorization, or medical management requirements.
  • View our billing guidance to understand which billing codes are appropriate for testing services.
  • Antibody testing is appropriate as a diagnostic test in limited circumstances and will not be a benefitable service when conducted for return to work or surveillance purposes.
  • Asymptomatic and pre-surgical COVID-19 diagnostic testing is covered when medically appropriate and supported by the accepted standards of current medical practice.

Stay Informed!

  • Very soon BCBSWY will be launching a new public website. Our web address will stay the same, www.BCBSWY.com, but the look will be updated and provider information will be organized by clinical resources and office resources. It’s intuitive to use and we hope you can easily find what you need but let us know if you need help finding something!

For more information see: CDC COVID-19 or State of Wyoming COVID-19.

ACA – Online Event Registration Form

Please enable JavaScript in your browser to complete this form.
Name
Email
How did you hear about this event?
Medicare - Event Registration
Medicare - Online Event Registration Form
Please enable JavaScript in your browser to complete this form.
Name
Email
How did you hear about this event?